

COMMISSIONED RESEARCH

Research analysts: Ludvig Svensson

COMPANY UPDATE 27 February 2025 Sweden Healthcare

Iconovo

Share price: SEK3.41 Fair value range: SEK7.0–12.0

Continued focus on licensing deals - Q4 review

Iconovo reported Q4 figures in line with our expectations. Net sales came in at SEK1.0m (1.0) and EBIT at SEK-10.8m (-9.9). Operating cash flow amounted to SEK-1.8m (-10.8) and the company ended 2024 with a cash balance of almost SEK30m.

During the quarter, Amnael completed its third clinical pharmacokinetic pilot study, comparing ICOres budesonide/formoterol to Symbicort Turbuhaler. The results were promising, and the company now plans to move forward with a pivotal study to confirm bioequivalence. If everything stays on track, ICOres budesonide/formoterol could be ready for European registration in 2026. Based on this timeline, we now assume that Iconovo will start receiving royalties from Amnael in late 2026, rather than our previous estimate of late 2025. As a result, we are adjusting our sales estimates.

The company communicated that it has expanded its partnering process for the anticipated ICOpre licensing agreement, now including regional players alongside global ones. With this update, we have slightly adjusted our assumptions and now expect three separate licensing deals, rather than a single global agreement. This means upfront payments will be spread out over 2025 and 2026, although the total amount remains unchanged at SEK35m.

After the quarter ended, the company announced a collaboration with Lonza, a leading Swiss contract manufacturing giant. The partnership aims to reformulate a biologic obesity drug into a more patient-friendly nasal inhalation format using the ICOone Nasal device. We see this as a significant market opportunity but the project is still in its early stages.

Following the report, we have made some adjustments to our cost estimates. We anticipate lower capex moving forward and expect personnel costs to decrease as well, given that the company has reduced its workforce by about 20% over the past year. Our fair value range stands at SEK7–12 (9–15). Looking ahead, we see a potential deal for ICOres as the next major catalyst for the share price.

Changes in this	report			Key figures (SEK)	2024	2025e	2026e	2027e	Share price - 5Y
	From	То	Chg	Sales (m)	3	20	82	120	100 n
EPS adj. 2025e	-0.08	-1.87	n.m.	EBITDA (m)	-30	-32	2	19	90 - M
EPS adj. 2026e	0.22	-0.13	n.m.	EBIT (m)	-41	-40	-4	13	80 -
EPS adj. 2027e	1.25	0.47	-62%	EPS	-2.47	-1.87	-0.13	0.47	70 -
· · · , · · · · ·				EPS adj.	-2.47	-1.87	-0.13	0.47	60 11 1 1
				DPS	0.00	0.00	0.00	0.00	50 -
				Sales growth Y/Y	-59%	580%	312%	47%	40 -
				EPS adj. growth Y/Y	+chg	+chg	+chg	+chg	30 -
Key facts				EBIT margin	n.m.	-201.8%	-4.5%	10.5%	20 -
No. shares (m)			21.2	P/E adj.	n.m.	n.m.	n.m.	7.2	10 -
Market cap. (USD	,		7	EV/EBIT	neg.	neg.	neg.	5.0	
Market cap. (SEK	,		72	EV/EBITA	neg.	neg.	neg.	5.0	Feb Feb Feb Feb Feb Feb
Net IB Debt. (SE			-8	EV/EBITDA	neg.	neg.	30.6	3.4	2020 2021 2022 2023 2024 2025
Adjustments (SEK	'		0	P/BV	0.6	0.6	0.6	0.6	Iconovo
EV (2025e) (SEKr	n)		64	Dividend yield	0.0%	0.0%	0.0%	0.0%	
Free float			65.8%	FCF yield	-68.8%	-59.5%	-10.3%	8.5%	OMX Stockholm_PI (Se) (Rebased)
Avg. daily vol. ('00	00)		33	Equity/Total Assets	88.7%	87.5%	84.8%	84.3%	High/Low (12M) SEK12.1/3.4
Risk			gh Risk	ROCE	-32.4%	-31.7%	-3.0%	10.7%	Perf. 3M 6M I2M YTD
Fiscal year end			ember	ROE adj.	-33.6%	-32.7%	-2.5%	8.6%	Abs29.3 -60.3 -56.8 -17.6
Share price as of	(CET) 2	7 Feb 202	5 15:57	Net IB debt/EBITDA	0.8	0.3	-0.9	-0.5	Rel38.8 -66.4 -70.8 -27.4

Source: Carnegie Research, FactSet, Millistream & company data

This report has been commissioned and sponsored by Iconovo. Commissioned research is considered to be marketing communication (i.e. not investment research under MiFID II). This material may be subject to restrictions on distribution in certain areas. For more information, see disclosures and disclaimers at the end of this report

Upcoming events

• QI Report: 24 Apr 2025



Equity story	
Near term: 6–12m	Iconovo is currently in partner discussions regarding its ICOpre project, and we believe that a deal could materialise in 2025. We consider this a very exciting opportunity given how significant a potential upfront payment could be in relation to the company's current market capitalisation. We are modelling total upfront payments of approximately SEK35m. As a reference transaction, we have used the 2017 deal between Ventura and Sandoz regarding their inhalable asthma/COPD generic, which included a USD5m upfront payment.
Long term: 5Y+	In the longer term, the success of Iconovo hinges on securing additional licensing deals with its inhalation devices to enable consistent, growing cash flow streams.
Key risks:	 Development risk Commercialisation risk Financial risk

Company description

lconovo assists generic companies and other pharmaceutical companies in developing inhalation drugs and inhalers. The business model is based on partner-funded product development combined with royalty revenues upon the product's market launch.

Key industry drivers

- Increased prevalence of chronic respiratory diseases
- Generic drug market growth
- Increased uptake for inhaled drugs

Industry outlook

 According to industry sources, the global market for drugs targeting chronic respiratory diseases was valued at over USD80bn in 2023 and is expected to grow at a CAGR of almost 6% to exceed USD140bn in 2032.

Largest shareholders

Gerald Engström	17.2%
Mats Johansson	7. 9 %
Nordnet Pensionsförsäkri	7.3%

Cyclicality Cyclicality: N/A Key peers

Nanologica, Corline Biomedical, Lipidor

Valuation and methodology


In our valuation of Iconovo, we use a DCF model. We expect the company to reach positive EBITDA in 2026. The company is asset light, and we expect it to have limited investment needs going forward. We believe that the company is poised to deliver significant growth in the coming years, followed by a transition to a more mature phase, culminating in a terminal year growth rate of 2% in our model. We model the company receiving SEK28m from its warrant programme and offset the dilution effect by assigning the company a higher WACC.

Fair value range 12m



The lower end of our fair value range is based on our DCF model using a WACC of 21%. This reflects a scenario where the company delivers on our expectations, but the sentiment for small-cap precommercialisation companies remains at current levels.

The upper end of our fair value range is based on our DCF model using a WACC of 16%. This reflects a scenario where the company delivers on our expectations and the sentiment for small-cap precommercialisation companies improves.



Source: Carnegie Research & company data



Estimate revisions

New 20	% ch. -76%	Old 107	New 82	% ch. -23%	Old 171	New 120	% ch. -30%
	-76%	107	82	-23%	171	120	-30%
-32	nm.	11	2	nm.	39	19	-52%
-40	nm.	5	-4	nm.	33	13	-62%
	-40	-40 nm.	-40 nm. 5	-40 nm. 5 -4	-40 nm. 5 -4 nm.		-40 nm. 5 -4 nm. 33 13 Source: Carnegie

Valuation

In our valuation of Iconovo, we use a DCF model. We expect the company to reach positive EBITDA in 2026. The company is asset light, and we expect it to have limited investment needs going forward. We believe that the company is poised to deliver significant growth in the coming years, followed by a transition to a more mature phase, culminating in a terminal year growth rate of 2% in our model. We model the company raising SEK25m in 2025/2026 and offset the dilution effect by assigning the company a higher WACC.

We reach a fair value range of SEK7–12 per share (9–15). The lower end of our fair value range is based on our DCF model using a WACC of 21%, and the upper end is based on our DCF model using a WACC of 16%.

					Average	Average year			
DCF assumptions - Summary	2025e	2026e	2027e	4-5	6-10	11-15	16-20	period	
Total sales growth	580.0%	311.6%	46.6%	44.5%	10.0%	4.4%	2.2%	2.0%	
EBITDA margin	-161.7%	2.8%	15.5%	26.3%	24.0%	25.2%	28.6%	30.0%	
Depreciation % of sales	-40.1%	-7.3%	-5.0%	-5.0%	-2.6%	-2.0%	-2.0%	-2.0%	
EBITA margin	-201.8%	-4.5%	10.5%	21.3%	21.4%	23.2%	26.6%	28.0%	
Amortisations % of sales	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
EBIT margin	-201.8%	-4.5%	10.5%	21.3%	21.4%	23.2%	26.6%	28.0%	
Capex % of sales	-50.1%	-12.2%	-8.3%	-3.0%	-3.0%	-2.4%	-2.0%	-2.0%	
Paid tax rate	0.0%	-20.6%	-20.6%	-20.6%	-20.6%	-20.6%	-20.6%	-20.6%	
NWC to sales	-43.0%	-11.0%	-6.0%	3.5%	8.4%	7.0%	7.0%	7.0%	
Sales	20	82	120	222	340	458	528	560	
EBITDA	-32	2	19	58	82	116	151	168	
Capex	-10	-10	-10	-7	-10	-11	-11	-11	
Taxes	0	I	-3	-10	-15	-22	-29	32	
Other	0	0	-2	-10	-3	-1	-1	451	
Free cash flow	-42	-7	4	32	53	81	111	640	
Discounted FCF	-38	-5	3	15	13	8	4	16	
Share of total discounted FCF	-30%	-4%	2%	24%	50%	30%	16%	12%	
Valuation	(curr.)m	Per share		v	VACC assur	nptions			
EV (discounted FCF)	125	5.9		R	isk free intere	est rate		4.0%	
- Net debt (2024)	25	1.2		D	ebt risk pren	nium		0.5%	
+ Associates	0	0.0		E	quity risk pre	mium		4.0%	
- Minority interest	0	0.0		E	quity beta			4.25	
- Outstanding warrants	0	0.0		Cost of Equity					
Other debt adjustments	0	0.0		T	ax rate			20.6%	
ESG penalty	0	0.0		A	fter tax cost	of debt		3.6%	
Equity value at YE (24)	150	7.1		E	quity weight			100%	
Time adjustment	5	0.2		v	VACC			21.0%	
Dividend	0	0.0							
Current equity value	155	7							

Source: Carnegie Research



					Average	year		Terminal
DCF assumptions - Summary	2025e	2026e	2027e	4-5	6-10	11-15	16-20	period
Total sales growth	580.0%	311.6%	46.6%	44.5%	10.0%	4.4%	2.2%	2.0%
EBITDA margin	-161.7%	2.8%	15.5%	26.3%	24.0%	25.2%	28.6%	30.0%
Depreciation % of sales	-40.1%	-7.3%	-5.0%	-5.0%	-2.6%	-2.0%	-2.0%	-2.0%
EBITA margin	-201.8%	-4.5%	10.5%	21.3%	21.4%	23.2%	26.6%	28.0%
Amortisations % of sales	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
EBIT margin	-201.8%	-4.5%	10.5%	21.3%	21.4%	23.2%	26.6%	28.0%
Capex % of sales	-50.1%	-12.2%	-8.3%	-3.0%	-3.0%	-2.4%	-2.0%	-2.0%
Paid tax rate	0.0%	-20.6%	-20.6%	-20.6%	-20.6%	-20.6%	-20.6%	-20.6%
NWC to sales	-43.0%	-11.0%	-6.0%	3.5%	8.4%	7.0%	7.0%	7.0%
Sales	20	82	120	222	340	458	528	560
EBITDA	-32	2	19	58	82	116	151	168
Capex	-10	-10	-10	-7	-10	-11	-11	-11
Taxes	0	I	-3	-10	-15	-22	-29	32
Other	0	0	-2	-10	-3	-1	-1	680
Free cash flow	-42	-7	4	32	53	81	111	869
Discounted FCF	-39	-5	3	17	17	13	8	48
Share of total discounted FCF	-17%	-2%	1%	15%	37%	27%	18%	21%
Valuation	(curr.)m	Per share		v	VACC assur	nptions		
EV (discounted FCF)	233	11.0		R	isk free intere	est rate		4.0%
- Net debt (2024)	25	1.2		D	ebt risk pren	nium		0.5%
+ Associates	0	0.0		Ed	quity risk pre	mium		4.0%
- Minority interest	0	0.0		E	quity beta			3.00
- Outstanding warrants	0	0.0		c	ost of Equit	;y		16.0%
Other debt adjustments	0	0.0		Ta	ax rate			20.6%
ESG penalty	0	0.0		A	fter tax cost	of debt		3.6%
Equity value at YE (24)	258	12.1		E	quity weight			100%
Time adjustment	6	0.3		v	VACC			16.0%
Dividend	0	0.0						
Current equity value	264	12						

Source: Carnegie Research

NPV/share sensitivity analysis, WACC and terminal growth rate

			WACC (%)									
		15%	16%	17%	18%	I 9%	20%	21%				
(%	3.5%	14.5	12.7	11.3	10.1	9.0	8.1	7.3				
growth (%)	3.0%	14.4	12.6	11.2	10.0	9.0	8.1	7.3				
o vt	2.5%	14.2	12.6	11.2	10.0	8.9	8.1	7.3				
	2.0%	14.1	12.5	11.1	9.9	8.9	8.0	7.3				
inal	1.5%	14.0	12.4	11.0	9.9	8.9	8.0	7.3				
Terminal	1.0%	13.9	12.3	11.0	9.8	8.8	8.0	7.2				
Чe	0.5%	13.8	12.3	10.9	9.8	8.8	8.0	7.2				

Source: Carnegie Research



Risks

Development risk: Iconovo's business model includes the development of both new proprietary drugs and generic versions of well-established inhalation products in collaboration with partners. The path to market for generics is significantly shorter compared to proprietary drugs. However, there are still risks associated with product development, such as failing to complete planned or ongoing studies required for potential regulatory submissions, or the possibility that regulatory authorities like the EMA or FDA may reject or delay product approval. Such scenarios could negatively impact the company's operations, financial position, and results.

Commercialisation risk: The company has not yet launched any products on the market and has therefore not generated large-scale sales, whether independently or through partners like Amneal or BNC Korea. The success of market launches heavily depends on the company's partners in regions where they hold commercial rights – an area over which Iconovo has no control. While a successful launch is not guaranteed, it is crucial for the company's future revenue, including royalties and milestone payments. Regarding sales managed independently in the Nordic region, risks remain concerning the recruitment of sales personnel, market acceptance, competition, and pricing.

Financial risk: We expect a continued need for additional capital, with no guarantees that the necessary funding can be secured on favourable terms or at all. Failure to raise the required capital would pose a risk to the company's ability to continue its operations.



Financial statements

Profit & loss (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Sales	12	12	18	15	17	7	3	20	82	120
COGS	-3	-1	-2	-7	-30	-11	-5	-10	-38	-55
Gross profit	9	11	16	9	-13	-3	-2	10	44	65
Other income & costs	-13	-20	-29	-30	-26	-32	-28	-42	-42	-47
Share in ass. operations and JV	0	0	0	0	0	0	0	0	0	0
EBITDA	-4	-9	-13	-21	-39	-36	-30	-32	2	19
Depreciation PPE	0	0	0	0	0	0	0	0	0	0
Depreciation lease assets	0	0	0	0	0	0	0	0	0	0
Amortisation development costs	0	0	0	0	0	0	0	0	0	0
Amortisation other intangibles	-2	-3	-4	-5	-9	-10	-11	-8	-6	-6
Impairments / writedowns	0	0	0	0	0	0	0	0	0	0
EBITA	-6	-12	-17	-27	-48	-46	-41	-40	-4	13
Amortization acquisition related	0	0	0	0	0	0	0	0	0	0
Impairment acquisition related	0	0	0	0	0	0	0	0	0	0
EBIT	-6	-12	-17	-27	-48	-46	-41	-40	-4	13
Share in ass. operations and JV	0	0	0	0	0	0	0	0	0	0
Net financial items	0	0	0	0	0	0	0	0	0	0
of which interest income/expenses	0	0	0	0	0	0	0	0	0	0
of which interest on lease liabilities	0	0	0	0	0	0	0	0	0	0
of which other items	0	0	0	0	0	0	0	0	0	0
Pre-tax profit	-6	-11	-17	-26	-48	-46	-41	-40	-4	13
Taxes	0	0	0	0	0	0	0	0	I	-3
Post-tax minorities interest	0	0	0	0	0	0	0	0	0	0
Discontinued operations	0	0	0	0	0	0	0	0	0	0
Net profit	-6	-11	-17	-26	-48	-46	-41	-40	-3	10
Adjusted EBITDA	-4	-9	-13	-21	-39	-36	-30	-32	2	19
Adjusted EBITA	-6	-12	-17	-27	-48	-46	-41	-40	-4	13
Adjusted EBIT	-6	-12	-17	-27	-48	-46	-41	-40	-4	13
Adjusted net profit	-6	-11	-17	-26	-48	-46	-41	-40	-3	10
Sales growth Y/Y	+chg	-1.4%	51.6%	-13.4%	11.1%	-58.6%	-58.5%	580.0%	311.6%	46.6%
EBITDA growth Y/Y	-chg	-chg	-chg	-chg	-chg	+chg	+chg	-chg	+chg	711.6%
EBITA growth Y/Y	-chg	-chg	-chg	-chg	-chg	+chg	+chg	+chg	+chg	+chg
EBIT growth Y/Y	-chg	-chg	-chg	-chg	-chg	+chg	+chg	+chg	+chg	+chg
EBITDA margin	-33.9%	-78.3%	-71.5%	-137.3%	-229.4%	-504.3%	na	-161.7%	2.8%	15.5%
EBITA margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	10.5%
EBIT margin	-48.9%	-100.3%	-93.9%	-172.0%	-282.5%	-646.8%	na	-201.8%	-4.5%	10.5%
Tax rate	na	na	na	na	na	na	na	na	20.6%	20.6%
Cash flow (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
EBITDA	-4	-9	-13	-21	-39	-36	-30	-32	2	19
Paid taxes	0	0	0	0	0	0	-1	0	ī	-3
Change in NWC	3	-3	-2	10	-3	-12	5	0	0	-2
Non cash adjustments	2	3	4	6	9	20	0	0	0	3
Discontinued operations	0	0	0	0	0	0	0	0	0	0
Total operating activities	1	-10	-12	-6	-34	-28	-25	-32	3	17
Capex tangible assets	-2	0	-3	-1	-5	-1	0	0	0	0
Capitalised development costs	-2	-8	-10	-25	-31	-22	-22	-10	-10	-10
Capex - other intangible assets	0	Ő	0	0	0	0	0	0	0	0
Acquisitions/divestments	ŏ	Ő	Ő	ő	õ	ő	ő	ŏ	ő	õ
Other non-cash adjustments	Ő	Ő	Ő	Ő	Ő	Ő	Ő	Ő	Ő	Ő
Total investing activities	-5	-8	-13	-26	-37	-23	-22	-10	-10	-10
Net financial items	0	0	0	0	0	0	0	0	0	0
Lease payments	ŏ	Ö	0	0	-2	-2	-3	-1	-1	-1
Dividend paid and received	0	0	0	0	-2	-2	-3	-1	-1	-1
Share issues & buybacks	37	56	I I	70	0	69	56	25	0	0
Change in bank debt	0	0	0	0	0	0	0	23	0	0
Other cash flow items	ŏ	ŏ	0	ő	0	Ő	ő	0	ů 0	Ő
Total financing activities	37	57	Ĭ	7Ĭ	-2	66	53	24	-1	-Î
Operating cash flow	-	-10	-12	-6	-34	-28	-25	-32	3	17
Free cash flow	-4	-10	-12	-8	-34 -73	-20 -54	-25	-32	-7	6
Net cash flow	-4 32	-18	-23	-32	-73	-54	-50	-43	-7	6
Change in net IB debt	32	39	-23	39	-73	15	10	-10	-6	6 7
-										
Capex / Sales NWC / Sales	13.0% -7.3%	2.4% -0.8%	14.2% 16.6%	8.4% -2.7%	31.9% -22.0%	10.1% -3.8%	0.0% 110.6%-	0.0% -42.2%	0.0% -10.7%	0.0% -6.8%

Source: Carnegie Research & company data



Financial statements, cont.

Balance sheet (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Acquired intangible assets	0	0	0	0	0	0	0	0	0	0
Other fixed intangible assets	9	16	23	42	68	85	101	93	87	81
Capitalised development	0	0	0	0	0	0	0	10	20	30
Tangible assets	4	2	4	5	20	16	15	15	15	15
Lease assets	0	0	0	0	0	0	0	0	0	0
Other IB assets (1)	0	0	0	0	0	0	0	0	0	0
Other non-IB assets	0	0	0	0	0	0	0	0	0	0
Fixed assets	13	18	27	47	88	101	116	118	122	126
Inventories (2)	0	0	0	0 3	0	0	0	0	0	0
Receivables (2) Proposid aver 8 other NIM/C items (2)	5	3 3	9 3	3	 9	4 5	0 0		2 3	4 5
Prepaid exp. & other NWC items (2)	2 0	0	0	0	9	0	0	0	0	0
IB current assets (1) Other current assets	0	0	0	0	0	0	0	0	0	0
Cash & cash equivalents (1)	53	89	62	95	13	18	30	12	4	10
Current assets	60	96	74	101	33	27	30	12	10	10
Total assets	73	114	101	149	121	128	146	13	132	144
Shareholders' equity	64	109	93	137	89	114	129	114	112	122
Minorities	0	0	0	0	0	0	0	0	0	0
Other equity	0	0	0	0	0	0	0	0	0	0
Total equity	64	109	93	137	89	114	129	114	112	122
Deferred tax	0	0	0	0	0	0	0	0	0	0
LT IB debt (I)	0	0	0 0	0 0	0 0	0	0 0	0	0	0
Other IB provisions (I)	0	0	0	0	8				2	0
Lease libilities Other non-IB liabilities	0	0	0	0	8	5 0	4 0	3 0	2	0
LT liabilities	0	0	0	0	8	5	4	3	2	Ĩ
ST IB debt (1)	0	0	0	0	0	3 0	4 0	3 0	0	0
	0	0	0	0	0	0	0	0	0	0
Payables (2) Accrued exp. 8 other $NN(C)$ items (2)	9	5	8	12	22	7	9	10	15	16
Accrued exp. & other NWC items (2) Other ST non-IB liabilities	0	0	0	0	2	3	3	3	3	6
Liabilities - assets held for sale	ő	0	0	0	0	0	0	0	0	0
Current liabilities	9	5	8	12	24	ıŏ	12	13	18	22
Total equity and liabilities	73	114	101	149	121	128	146	131	132	144
Net IB debt $(=1)$	-53	-89	-62	-95	-6	-14	-25	-8	-2	-9
Net working capital (NWC) (=2)	-2	2	4	-5	-2	2	-8	-9	-9	-7
Capital employed (CE)	64	109	93	137	97	118	134	118	114	123
Capital invested (CI)	11	20	31	42	86	103	107	99	93	88
Equity / Total assets	88%	96%	92%	92%	74%	89%	89%	88%	85%	84%
Net IB debt / EBITDA	13.2	9.7	4.9	4.5	0.1	0.4	0.8	0.3	-0.9	-0.5
Per share data (SEK)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Adj. no. of shares in issue YE (m)	0.00	7.78	7.78	8.85	8.85	11.76	21.22	21.22	21.22	21.22
Diluted no. of Shares YE (m)	0.00	7.78	7.78	8.85	8.85	11.76	21.22	21.22	21.22	21.22
EPS	na	-2.93	-2.20	-3.15	-5.44	-4.45	-2.47	-1.87	-0.13	0.47
EPS adj.	na	-2.93	-2.20	-3.15	-5.44	-4.45	-2.47	-1.87	-0.13	0.47
CEPS	na	-2.27	-1.69	-2.50	-4.64	-3.70	-2.01	-1.55	0.10	0.71
DPS	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
BVPS	na	14.0	11.9	15.5	10.1	9.66	6.09	5.39	5.26	5.73
Performance measures	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
	-18.2%	-13.2%	-17.0%	-22.8%	-42.6%	-45.3%	-33.6%	-32.7%	-2.5%	8.6%
Adj. ROCE pre-tax Adj. ROIC after-tax	na	-12.8% -77.0%	-15.5% -66.0%	-22.7% -72.6%	-40.9% -75.6%	-42.1% -48.5%	-32.4% -39.1%	-31.7% -39.0%	-3.0% -3.1%	10.7% 11.1%
Adj. KOIC alter-tax	na	-77.0%	-00.0%	-72.0%	-75.6%	-40.3%	-37.1%	-37.0%	-3.1%	11.1/6
Valuation	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
FCF yield	-6.2%	-24.2%	-33.9%	-43.6%	-100.2%	-74.1%	-68.8%	-59.5%	-10.3%	8.5%
Dividend yield YE	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Dividend payout ratio	na	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Dividend + buy backs yield YE	nm	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
EV/Sales YE	200	44.08	18.56	38.04	24.99	17.27	21.32	3.21	0.86	0.52
	neg.									
EV/EBITDA YE	13.2	neg.	30.6	3.4						
EV/EBITA YE	9.1	neg.	neg.	5.0						
EV/EBITA adj. YE	9.1	neg.	neg.	5.0						
EV/EBIT YE	9.1	neg.	neg.	5.0						
P/E YE										7.2
P/E adj. YE	na na	nm nm	nm nm	7.2						
P/BV YE	na	5.58	4.23	4.97	4.86	1.20	0.68	0.63	0.65	0.59
									0.05	0.57
Share price YE (SEK)	35.0	78.0	50.4	77.0	49.0	11.6	4.14	3.41		

Source: Carnegie Research & company data



Disclosures and disclaimers

Carnegie Investment Bank AB

Carnegie Investment Bank AB (publ.) is a leading investment bank with a Nordic focus. The Carnegie group of companies, together "Carnegie", generates added value for institutions, companies and private clients in the areas of trade in securities, investment banking and private banking. Carnegie has approximately 600 employees, located in offices in six countries

Valuation, methodology, and assumptions

Commissioned research reports include the analyst's assessment of a fair value range over the coming six to 12 months based on various fundamental valuation methods. A commonly used method is DCF valuation, where future cash flows are discounted to today. Analysts may also use different valuation multiples, e.g. P/E ratio and EV/EBIT multiples, relative to industry peers. For companies where it is appropriate, a fair value range can also be based on the analyst's assessment of a fair ratio relative to the net asset value of the company. Fair value ranges represent the assessment of the analyst(s) at the time of writing

Frequency of update

Carnegie's research analysis consists of case-based analyses, which implies that the frequency of the analytical report may vary over time. Unless otherwise expressly stated in the report, the analysis is updated when considered necessary by the research department, for example in the event of significant changes in market conditions or events related to the issuer/the financial instrument.

Analyst certification

The research analyst or analysts responsible for the content of this commissioned research report certify that, notwithstanding the existence of any potential conflicts of interests referred to herein, the views expressed in this commissioned research report accurately reflect the research analyst's personal views about the companies and securities covered. It is further certified that the research analyst has not been, nor is or will be, receiving direct or indirect compensation related to the specific ratings or views contained in this commissioned research report.

Potential conflicts of interest

Carnegie, or its subsidiaries, may from time to time perform investment banking or other services for, or solicit investment banking or other business from, any company mentioned in this report. Any such publicly announced business activity, during the past 12 months, will be referred to in this commissioned research report. A set of rules handling conflicts of interest is implemented in the Carnegie Group. Investment Banking and other business departments in Carnegie are surrounded by information barriers to restrict the flows of sensitive information. Persons outside such barriers may gain access to sensitive information only after having observed applicable procedures. The remuneration of persons involved in preparing this commissioned research report is not tied to investment banking transactions performed by Carnegie or a legal person within the same group.

Confidential and non-public information regarding Carnegie and its clients, business activities and other circumstances that could affect the market value of a security ("sensitive information") is kept strictly confidential and may never be used in an undue manner.

Internal guidelines are implemented in order to ensure the integrity and independence of research analysts. In accordance with the guidelines the research department is separated from the Investment Banking department and there are no reporting lines between the research department and Investment Banking. The guidelines also include rules regarding, but not limited to, the following issues; contacts with covered companies, prohibition against offering favourable recommendations, personal involvement in covered companies, participation in investment banking activities, supervision and review of research reports, analyst reporting lines and analyst remuneration.

Other material conflicts of interest

This report was commissioned and sponsored by the issuer (issuer-paid research).

Distribution restrictions

This commissioned research report is intended only for distribution to professional investors. Such investors are expected to make their own investment decisions without undue reliance on this commissioned research report. This commissioned research report does not have regard to the specific investment objectives, financial situation or particular needs of any specific person who may receive it. Investors should seek financial advice regarding the appropriateness of investing in any securities discussed in this commissioned research report and should understand that statements regarding future prospects may not be realized. Past performance is not necessarily a guide to future performance. Carnegie and its subsidiaries accept no liability whatsoever for any direct or consequential loss, including, without limitation, any loss of profits arising from the use of this commissioned research report or its contents. This commissioned research report may not be reproduced, distributed or published by any recipient for any purpose. The document may not be distributed to persons that are citizens of or domiciled in any country in which such distribution is prohibited according to applicable laws or other regulations.

This commissioned research report is distributed in Sweden by Carnegie Investment Bank AB. Carnegie Investment Bank AB is a bank incorporated in Sweden with limited liability which is authorised and regulated by the Swedish Financial Supervisory Authority (Finansinspektionen). In Finland this commissioned research report is issued by Carnegie Investment Bank AB, Finland Branch. The Finland branch is authorised by the Swedish Financial Supervisory Authority and subject to limited regulation by the Finnish Financial Supervisory Authority (Finansiti/avonta). In Norway this commissioned research report is issued by Carnegie AS, a wholly-owned subsidiary of Carnegie Investment Bank AB. Carnegie AS is regulated by the Financial Supervisory Authority of Norway (Finanstilsynet). In Denmark this commissioned research report is issued by Carnegie Investment Bank AB, Denmark Branch. The Denmark branch is authorised by the Swedish Financial Supervisory Authority and subject to limited regulation by the Danish Financial Supervisory Authority (Finanstilsynet).

This commissioned research report is distributed in the US by Carnegie, Inc., a US-registered broker-dealer and a member of FINRA and SIPC. Carnegie's research analysts located outside of the US are employed by non-US affiliates of Carnegie Inc. ("non-US affiliates") that are not subject to FINRA regulations. Generally, Carnegie research analysts are not registered with or qualified as research analysts with FINRA, and therefore are not subject to FINRA rule 2241 restrictions intended to prevent conflicts of interest by, among other things, prohibiting certain compensation practices, restricting trading by analysts and restricting communications with the companies that are the subject of the research report. Research reports distributed in the U.S. are intended solely for major US institutional investors and US institutional investors as defined under Rule 15a-6 of the Securities Exchange Act of 1934. This commissioned research report is provided for informational purposes only and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of any offer to buy any securities. Reports regarding equity products are prepared by non-US affiliates of and distributed in the United States by Carnegie Inc. under Rule 15a-6(a)(3). When distributed by Carnegie Inc, Carnegie Inc, takes responsibility for the commissioned research report. Any US person who wishes to effect transactions based on this commissioned research report should contact Carnegie Inc. Investors in the US should be aware that investing in non-US securities entails certain risks. The securities of non-US issuers may not be registered with, or be subject to, the current information reporting and audit standards of the US Securities and Exchange Commission. This commissioned research report has been issued in the UK by Carnegie UK which is the UK Branch of Carnegie Investment Bank AB. Carnegie Investment Bank AB. Carnegie Investment Bank AB. Carnegie Investment Bank AB. Carnegie Investment Bank AB.

Research Disclaimer

This commissioned research report is provided solely for information. It does not constitute or form part of, and shall under no circumstances be considered as an offer to sell or a solicitation of an offer to purchase or sell any relevant financial instrument.

This commissioned research report has been requested and paid for by the issuer and should therefore be considered a marketing communication (i.e. not investment research). Payment for the report has been agreed in advance on a non-recourse basis. As commissioned research, this material can be considered an acceptable minor non-monetary benefit under MiFID II. It has not been prepared in accordance with the legal requirements designed to promote the independence of investment research. However, it is still subject to a prohibition on dealing ahead of the dissemination of the report.

Carnegie Investment Bank AB is responsible for the preparation of this commissioned research report in Sweden, Finland, Denmark, and the UK. Carnegie AS is responsible for the preparation of this commissioned research report in Norway. Carnegie Inc. is responsible for this research report in the US.

The information in this commissioned research report was obtained from various sources. While all reasonable care has been taken to ensure that the information is true and not misleading. Carnegie gives no representation or warranty, express or implied, about its accuracy or completeness. Carnegie, its subsidiaries and any of their officers or directors may have a position, or otherwise be interested in, transactions in securities that are directly or indirectly the subject of this commissioned research report. Any significant financial interests held by the analyst, Carnegie or a legal person in the same group in relation to the issuer will be referred to in the company-specific disclosures.

Company specific disclosures

The following disclosures relate to relationships between Carnegie Investment Bank AB (with its subsidiaries, "Carnegie") and the issuer or an affiliate.

 $\ensuremath{\mathsf{Parts}}$ of this commissioned research report may have been submitted to the issuer prior to its publication.

Copyright © 2025 Carnegie



Commissioned Research sponsored by Iconovo

27 February 2025

Carnegie Investment Bank AB

Regeringsgatan 56 SE-103 38 Stockholm Tel +46 8 5886 88 00 Fax +46 8 5886 88 95 www.carnegie.se A member of the Stockholm Stock Exchange

Carnegie AS

Fjordalleen 16, 5th Floor PO Box 684, Sentrum NO-0106 Oslo Tel +47 22 00 93 00 Fax +47 22 00 94 00 www.carnegie.no A member of the Oslo Stock Exchange Carnegie Investment Bank, Denmark Branch Overgaden neden Vandet 9B PO Box 1935 DK-1414 Copenhagen K Tel +45 32 88 02 00 Fax +45 32 96 10 22 www.carnegie.dk A member of the Copenhagen Stock Exchange

Carnegie, Inc.

20 West 55th St. , New York N.Y. 10019 Tel +1 212 262 5800 Fax +1 212 265 3946 www.carnegiegroup.com Member FINRA / SIPC Carnegie Investment Bank AB, Finland Branch Eteläesplanadi 2 PO Box 36 FI-00131 Helsinki Tel +358 9 618 71 230 Fax +358 9 618 71 720 www.carnegie.fi A member of the Helsinki Stock Exchange

Carnegie Investment Bank AB, UK Branch

Finwell House, 26 Finsbury Square London EC2A IDS Tel +44 20 7216 4000 Fax +44 20 7417 9426 www.carnegie.co.uk Regulated by the FCA in the conduct of Designated Investment Business in the UK